Scilex Subsidiary Sells ACEA Pharma for $1 Billion Stake in Phoenix Asia, Creating New Public Entity

summarizeSummary

Scilex's indirect subsidiary, ACEA Therapeutics, Inc., has sold its wholly-owned subsidiary, ACEA Pharma, Inc., to Phoenix Asia Holdings Limited for $1 billion in Phoenix Asia shares, resulting in ACEA Thera owning 82% of the newly public Phoenix Asia (to be renamed ACEA Pharma, Inc.).

check_boxKey Events

• Subsidiary Divestiture and Strategic Investment

  Scilex's indirect subsidiary, ACEA Therapeutics, Inc., sold its wholly-owned subsidiary, ACEA Pharma, Inc., to Phoenix Asia Holdings Limited.

• $1 Billion Equity Consideration

  In exchange for ACEA Pharma, ACEA Thera received 100,000,000 newly-issued ordinary shares of Phoenix Asia, valued at $10.00 per share, totaling $1,000,000,000.

• Majority Stake in New Public Entity

  Upon closing, ACEA Thera is expected to own approximately 82% of Phoenix Asia, which will be renamed ACEA Pharma, Inc. and listed on Nasdaq.

• Expected Closing

  The transaction is subject to customary closing conditions and is anticipated to close within the second quarter of 2026.

auto_awesomeAnalysis

This transaction is highly significant for Scilex Holding Co., as it involves a $1 billion valuation for its wholly-owned subsidiary, ACEA Pharma, Inc., which is being spun out into a new publicly traded entity, Phoenix Asia Holdings Limited. Scilex's indirect subsidiary, ACEA Therapeutics, Inc., will retain an 82% ownership stake in the renamed Phoenix Asia (ACEA Pharma, Inc.), effectively creating a new, substantial public asset under Scilex's control. This move could unlock considerable value for Scilex shareholders, especially given the transaction's value far exceeds Scilex's current market capitalization. The deal is subject to customary closing conditions and is expected to finalize in Q2 2026.